Lexicon Pharmaceuticals Inc.

06/09/2025 | Press release | Distributed by Public on 06/09/2025 08:04

Initial Statement of Beneficial Ownership (Form 3)

FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5
(Print or Type Responses)
1. Name and Address of Reporting Person *
Gopinathan Suma
2. Date of Event Requiring Statement (Month/Day/Year)
06/01/2025
3. Issuer Name and Ticker or Trading Symbol
LEXICON PHARMACEUTICALS, INC. [LXRX]
(Last) (First) (Middle)
2445 TECHNOLOGY FOREST BLVD, 11TH FLOOR
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
SVP, Discovery
5. If Amendment, Date Original Filed (Month/Day/Year)
(Street)
THE WOODLANDS, TX 77381
6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 74,520 D
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) (1) 02/09/2027 Common Stock 480 $14.44 D
Stock Option (Right to Buy) (1) 02/08/2028 Common Stock 1,000 $9.79 D
Stock Option (Right to Buy) (1) 02/07/2029 Common Stock 2,000 $5.16 D
Stock Option (Right to Buy) (1) 02/06/2030 Common Stock 4,800 $3.31 D
Stock Option (Right to Buy) (1) 02/11/2031 Common Stock 4,000 $8.38 D
Stock Option (Right to Buy) (1) 02/10/2032 Common Stock 10,000 $3.2 D
Restricted Stock Units (2) (2) Common Stock 14,000 (3) D
Stock Option (Right to Buy) (1) 02/09/2033 Common Stock 28,000 $2.43 D
Restricted Stock Units (2) (2) Common Stock 40,620 (3) D
Stock Option (Right to Buy) (1) 02/08/2034 Common Stock 60,930 $2.15 D
Restricted Stock Units (2) (2) Common Stock 196,920 (3) D
Stock Option (Right to Buy) (1) 02/13/2035 Common Stock 196,920 $0.695 D
Stock Option (Right to Buy) (1) 02/28/2026 Common Stock 3,790 $9.07 D

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Gopinathan Suma
2445 TECHNOLOGY FOREST BLVD
11TH FLOOR
THE WOODLANDS, TX 77381
SVP, Discovery

Signatures

/s/ Suma Gopinathan, M.S, Ph.D. 06/09/2025
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter.
(2) Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.
(3) Each restricted stock unit represents a contingent right to receive one share of common stock.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.
Lexicon Pharmaceuticals Inc. published this content on June 09, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on June 09, 2025 at 14:04 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io